AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its ...

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, its largest buyout in more than five years.

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Key market opportunities for SKYRIZI include its expansion across multiple indications such as psoriasis and IBD, showcasing best-in-class efficacy and strong clinical responses. Strategic positioning ...

A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.

On June 22, AbbVie announced that it would acquire Apogee Therapeutics (APGE +0.24%), a biotech company focused on developing medicines for immunological and inflammatory diseases. AbbVie will pay ...

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen ...

AbbVie Inc. agreed to buy Apogee Therapeutics Inc. for $10.9 billion to bolster its anti-inflammatory drug portfolio amid growing competition for its best-selling product, Skyrizi.